Literature DB >> 11100819

Suppression of cell invasion on human malignant glioma cell lines by a novel matrix-metalloproteinase inhibitor SI-27: in vitro study.

M Noha1, D Yoshida, K Watanabe, A Teramoto.   

Abstract

Matrix metalloproteinase (MMP) has come to be highlighted by its close relation to the cell invasion of gliomas. Suppression of MMP activity in malignant glioma cells would be meriting to local delivery of genes or chemotherapeutic agents. In this study, we employed a novel MMP inhibitor, SI-27 to investigate inhibition of cell invasiveness in human malignant glioma cell lines, U87MG, U251MG, and U373MG. We evaluated with zymogram, reverse zymogram, and cell invasion assay after exposure of SI-27 for 24 h followed by preliminary MTT assay to find non-cytotoxic dose range, 5, 10, 50, 100 microg/ml compared with non-treatment group as the control. Common to three glioma cell lines, zymogram disclosed that expressions of MMP-2 and -9 were suppressed in a dose-dependent fashion, meanwhile those of tissue inhibitor of MMP (TIMMP) in reverse zymogram were not. The numbers of invading cells through Boyden chamber were significantly reduced in a dose-dependent manner, while those with 5 microg/ml were not diminished common to those three lines. In conclusion, dose concentration ranging 10-100 microg/ml of SI-27 inhibited MMP-2 and -9 mediated cell invasiveness in malignant glioma cell lines. This is the first report for chemotherapeutic effect of SI-27 on glioma cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11100819     DOI: 10.1023/a:1006424424119

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  Release of collagen type IV degrading activity from C6 astrocytoma cells and cell density.

Authors:  M Tamaki; W McDonald; R F Del Maestro
Journal:  J Neurosurg       Date:  1996-06       Impact factor: 5.115

Review 2.  Matrix metalloproteinases: a review.

Authors:  H Birkedal-Hansen; W G Moore; M K Bodden; L J Windsor; B Birkedal-Hansen; A DeCarlo; J A Engler
Journal:  Crit Rev Oral Biol Med       Date:  1993

Review 3.  Molecular aspects of tumor cell invasion and metastasis.

Authors:  S Aznavoorian; A N Murphy; W G Stetler-Stevenson; L A Liotta
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

4.  Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.

Authors:  J C Tonn; S Kerkau; A Hanke; H Bouterfa; J G Mueller; S Wagner; G H Vince; K Roosen
Journal:  Int J Cancer       Date:  1999-03-01       Impact factor: 7.396

5.  Expression of 72 kDa type IV collagenase and invasion activity of human glioma cells.

Authors:  T Abe; T Mori; K Kohno; M Seiki; T Hayakawa; H G Welgus; S Hori; M Kuwano
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

6.  Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors.

Authors:  J S Rao; P A Steck; S Mohanam; W G Stetler-Stevenson; L A Liotta; R Sawaya
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

7.  Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors.

Authors:  T Nakagawa; T Kubota; M Kabuto; K Sato; H Kawano; T Hayakawa; Y Okada
Journal:  J Neurosurg       Date:  1994-07       Impact factor: 5.115

8.  In vitro inhibition of cell proliferation, viability, and invasiveness in U87MG human glioblastoma cells by estramustine phosphate.

Authors:  D Yoshida; J M Piepmeier; A Teramoto
Journal:  Neurosurgery       Date:  1996-08       Impact factor: 4.654

9.  A matrix metalloproteinase expressed on the surface of invasive tumour cells.

Authors:  H Sato; T Takino; Y Okada; J Cao; A Shinagawa; E Yamamoto; M Seiki
Journal:  Nature       Date:  1994-07-07       Impact factor: 49.962

10.  Raised levels of latent collagenase activating angiogenesis factor (ESAF) are present in actively growing human intracranial tumours.

Authors:  C M Taylor; J B Weiss; R H Lye
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

View more
  8 in total

Review 1.  The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis.

Authors:  T E VanMeter; H K Rooprai; M M Kibble; H L Fillmore; W C Broaddus; G J Pilkington
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

2.  MMP inhibitor Ilomastat induced amoeboid-like motility via activation of the Rho signaling pathway in glioblastoma cells.

Authors:  Shaofeng Yan; Hao Xue; Ping Zhang; Xiao Han; Xing Guo; Guang Yuan; Lin Deng; Gang Li
Journal:  Tumour Biol       Date:  2016-10-14

3.  Inhibition of Necl-5 (CD155/PVR) reduces glioblastoma dispersal and decreases MMP-2 expression and activity.

Authors:  Brian M Enloe; Daniel G Jay
Journal:  J Neurooncol       Date:  2010-08-03       Impact factor: 4.130

4.  Inhibition of cell invasion by indomethacin on glioma cell lines: in vitro study.

Authors:  Maode Wang; Daizo Yoshida; Shouxun Liu; Akira Teramoto
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

5.  Suppression of matrix metalloproteinase activity by SI-27: detection by a new activity assay with S-2444, a specific chromogenic peptide.

Authors:  Daizo Yoshida; Kunihiro Watanabe; Masahiro Noha; Hiroshi Takahashi; Akira Teramoto
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

6.  Drug-induced apoptosis by a matrix metalloproteinase inhibitor, SI-27 on human malignant glioma cell lines; in vitro study.

Authors:  Ryuzaburo Kanazawa; Daizo Yoshida; Hiroshi Takahashi; Yuichi Sugisaki; Satoru Suzuki; Akira Teramoto
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

Review 7.  Emerging Roles of the Endoplasmic Reticulum Associated Unfolded Protein Response in Cancer Cell Migration and Invasion.

Authors:  Celia Maria Limia; Chloé Sauzay; Hery Urra; Claudio Hetz; Eric Chevet; Tony Avril
Journal:  Cancers (Basel)       Date:  2019-05-06       Impact factor: 6.639

Review 8.  CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma.

Authors:  Kyle B Lupo; Sandro Matosevic
Journal:  J Hematol Oncol       Date:  2020-06-12       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.